A Phase 2 interventional study of Radiotherapy alone and Concurrent chemoradiotherapy in Nasopharyngeal Carcinoma, sponsored by Zhejiang Cancer Hospital. Status unknown at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Zhejiang Cancer Hospital · Phase 2, Interventional, and Treatment
Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
To evaluate concurrent chemotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy
6,741 studies on the registry are indexed under Carcinoma; 1,163 are open to participants now.
This study's planned enrollment of 122 is above the median of 45 across 5,174 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Zhejiang Cancer Hospital is the lead sponsor of 271 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Radiotherapy alone was given.
Radiation: Radiotherapy alone
Concurrent cisplatin-based radiotherapy was given.
Radiation: Concurrent chemoradiotherapy
therapeutic success
A combined primary end point, named "therapeutic success"(TS), was used; it took into account activity, toxicity, and compliance.A TS was defined as a patient completing radiotherapy at the planned dose and schedule (no re-treatment delays beyond 2 weeks), and having an objective response (either complete or partial based on RECIST criteria) without (1) grade 3-4 nonhematological toxicity, (2) complications associated with hematologic toxicity such as febrile neutropenia, infection, bleeding, or transfusion, or (3) any toxicity leading to hospitalization or death.
Time frame: From date of treatment until the date of completing treatment 1 month later
This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Cancer Hospital